

Course on Molecular Pathology and Targeted Therapy in Endometrial and Ovarian Cancer

November 17-18, 2025
VIENNA, AUSTRIA



Scientific Programme

Chairs: Nicole Concin, Xavier Matias-Guiu, Anna Fagotti, Iain McNeish
17 & 18 November 2025
Vienna, Austria

Day 1: November 17, 2025			
08:00 Registration at the venue and welcome coffee			
8:20	Introduction, Welcome	Chairs: N Concin, X Matias-Guiu, A Fagotti, I McNeish	10'
OVARIAN CARCINOMA Chairs of the OC day: A Fagotti, I McNeish			
	Molecular Markers in High Grade Ovarian Cancer		
8:30	Precursor lesions of high grade serous carcinoma: genomic features and possible therapeutic implications	Iain McNeish	15'
	Discussion		10'
8:55	Secondary prevention in OC: is it possible?	Anna Fagotti	15'
	Discussion		10'
9:20	Artificial intelligence in ovarian cancer histopathology	Konstantinos Zormpas-Petridis	15'
	Discussion		10'
9:45	Do liquid biopsies have a role to play in diagnosis and monitoring in ovarian cancer?	Iain McNeish	15'
	Discussion		10'
Coffee break 30 min (10:10 – 10:40)			
10:40	HRD test: pitfalls and new possible approach	Alexandra Leary	15'
	Discussion		10'
11:05	Are all HRD+ OC platinum and PARP sensitive? And why do some HRD- OC respond so well?	Iain McNeish	15'
	Discussion		10'
11:30	Targeting folate receptor alpha in OC: future perspectives, other than the pl-resistant setting.	Penault Llorca	15'
	Discussion		10'
11:55	Her-2 amplification in OC: which expectations for therapy?	Christian Marth	15'
	Discussion		10'
12:20	Tumour profiling analysis of mucinous OC and possible therapeutic implications	Xavier Matias-Guiu	15'
	Discussion		10'

Course on Molecular Pathology and Targeted Therapy in Endometrial and Ovarian Cancer

November 17-18, 2025
VIENNA, AUSTRIA



12:45	Heterogeneity and immunobiology of OC and impact on IO resistance in OC	Jonathan Ledermann	15'
	Discussion		10'
Lunch break 60min (13:10-14:10)			
	Rare ovarian tumours		
14:10	Molecular/genetic pathways and treatment of low-grade ovarian tumours	Christoph Grimm	15'
	Discussion		10'
14:35	Integration of molecular pathology to define patients for fertility sparing management in endometrial and ovarian tumours: too early?	Anna Fagotti	15'
	Discussion		10'
15:00	Basket trials in rare OC: are they feasible?	TBC	15'
	Discussion		10'
Coffee break 30 min (15:25-15:55)			
	Case studies		
15:55	Case 1		5'
	Discussion		15'
16:15	Case 2		5'
	Discussion		15'
16:35	Case 3		5'
	Discussion		15'
16:55	Wrap up Day 1	Chairs of the day: A Fagotti, I McNeish	5'
Welcome dinner (20:00) Meeting point: Hotel lobby			
Day 2: November 18, 2025			
08:30	Welcome Day 2	Chairs: N Concin, X Matias-Guiu, A Fagotti, I McNeish	10'
ENDOMETRIAL CARCINOMA Chairs of the EC day: N Concin & X Matias-Guiu			
	Tumor Biology and Testing in Endometrial Carcinoma		
8:40	The game-changer: Molecular classification of Endometrial carcinomas	Xavier Matias-Guiu	15'
	Discussion		10'
09:05	Biomarkers beyond Molecular classification: ER/PR, HER2, Trop2 and many more – what, when, how and why to test ?	Sigurd Lax	15'
	Discussion		10'
9:30	LVSI: no/focal/substantial How to determine, to cluster und to guide treatment?		25'

Course on Molecular Pathology and Targeted Therapy in Endometrial and Ovarian Cancer

November 17-18, 2025
VIENNA, AUSTRIA



	-the clinical experience - the pathological point of view - implications according to ESGO-ESTRO-ESP GLs	Ilaria Capasso (8') Alicia Leon Castilio (8') Remi Nout (8')	
	Discussion		10'
Coffee break 20min (10:05-10:25)			
10:25	"Synchronous" tumours: are they synchronous?	Xavier Matias-Guiu	15'
	Discussion		10'
10:50	Integrating it all: AI and machine learning in endometrial carcinoma	Alicia Leon Castilio	15'
	Discussion		10'
11:15	The hereditary: Lynch syndrome (testing, tailored surveillance, prophylactic surgery etc)	Stephan Polterauer	15'
	Discussion		10'
Coffe break 15 min (11:40-11:55)			
	Path to clinic		
11:55	Risk group stratification (including FIGO 2023 staging)	Remi Nout & Nicole Concin	20'
	Discussion		10'
Lunch break 60min (12:25-13:25)			
13:25	MMRd, the most clear molecular subgroup?	Jonathan Ledermann	10'
	Discussion		10'
13:45	None-MMRd: POLEmut, the best	Ilaria Capasso	15'
	Discussion		10'
14:10	None-MMRd: p53 abnormal, the worst	Nicole Concin	15'
	Discussion		10'
14:35	None-MMRd: NSMP, the biggest and least specific?	Stephan Polterauer	15'
	Discussion		10'
Coffee break 20 min (15:00-15:20)			
15:20	Biomarker-driven clinical approaches beyond molecular subgroups	Christian Marth	15'
	Discussion		10'
15:45	The challenges in biomarker- driven treatment approaches	Alexandra Leary	15'
	Discussion		10'
Coffee break 10min (16:10-16:20)			
	Case studies		
16:20	Case 1	Stamatios Petousis	5'
	discussion		10'

Course on Molecular Pathology and Targeted Therapy in Endometrial and Ovarian Cancer

November 17-18, 2025
VIENNA, AUSTRIA



16:35	Case 2	Veronika Seebacher Shariat	5`
	Discussion		10`
16:50	Case 3	Richard Schwameis	5`
	Discussion		10`
17:05	Wrap up Day 2	Charis of the day: N Concin, X Matias-Guiu	5`
17:10	Closing, evaluations	Chairs: N Concin, X Matias Guiu, A Fagotti, I McNeish	5`